Buy or sell BenevolentAI stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

BenevolentAI Stock

A British company harnessing the power of AI to enhance and accelerate global scientific discovery

Founded

2013

Total Funding

$100M

About BenevolentAI Stock

BenevolentAI was founded in 2013 (originally as Stratified Medical) by the management team of Proximagen who have a track record of building highly successful and disruptive technology companies. They saw the opportunity to forge a union between technology and bioscience using AI in order to accelerate biomedical discoveries. Between Q4 2013 and Q3 2015 the company has conducted four rounds of funding, raising a total of £87.72 million (circa $100m) at a final valuation of $1.781 billion. Lead investors included Woodford Investment Management, Lansdowne Partners, Lundbeck H/S and Upsher Smith Laboratories Inc. In 2014 benevolent.ai signed a licence deal with a US pharmaceutical organisation based on two novel targets for the treatment of Alzheimer’s disease. In September 2016, the company changed its name from Stratified Medical to benevolent.ai to better reflect the wider application of its technology outside of human healthcare and drug discovery.

Funding History

August 2015$100M

Management

Co Founder - Head of Corporate Development

Michael Brennan

Co Founder - Chief Development Officer

Brent Gutekunst

Co Founder - VP Business Development

Ivan Griffin

VP Engineering

Dewet Diener

CEO BenevolentTech

Jerome Pesenti

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from BenevolentAI or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo